Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb;107(2):286-95.
doi: 10.1038/ajg.2011.358. Epub 2011 Nov 8.

IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment

Olafur S Palsson  1 , Jeffrey S Baggish, Marsha J Turner, William E Whitehead
Affiliations

IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment

Olafur S Palsson et al. Am J Gastroenterol. 2012 Feb.

Abstract

Objectives: The objectives of this study were to determine how variable stool consistency is in patients with irritable bowel syndrome (IBS) and to assess the relationship between stool consistency and gastrointestinal symptoms.

Methods: Individuals with a physician diagnosis of IBS were recruited by advertisement. Enrollment questionnaires included the Rome III Diagnostic Questionnaire and IBS Symptom Severity Scale. Then, 185 patients meeting the Rome criteria for IBS rated the consistency (using the Bristol Stool Scale) of each bowel movement (BM) for 90 days and whether the BM was accompanied by pain, urgency, or soiling. Each night, they transferred BM ratings from a paper diary to an internet form and also reported the average daily intensity of abdominal pain, bloating, bowel habit dissatisfaction, and life interference of bowel symptoms. Only the longest sequence of consecutive days of diary data was used in the analysis (average of 73 days).

Results: Patients were 89% females with average age 36.6 years. Among the patients, 78% had both loose/watery and hard/lumpy stools; the average was three fluctuations between these extremes per month. The proportion of loose/watery stools correlated r=0.78 between the first and second months and the proportion of hard/lumpy stools correlated r=0.85 between months. Loose/watery stools were associated with more BM-related pain, urgency, and soiling than hard/lumpy or normal stools; however, IBS-C patients had significantly more BM-unrelated abdominal pain, bloating, dissatisfaction with bowel habits, and life interference than IBS-D patients. Questionnaires overestimated the frequency of abnormal stool consistency and gastrointestinal symptoms compared with diaries.

Conclusions: Stool consistency varies greatly within individuals. However, stool patterns are stable within an individual from month to month. The paradoxical findings of greater symptom severity after individual loose/watery BMs vs. greater overall symptom severity in IBS-C implies different physiological mechanisms for symptoms in constipation compared with diarrhea. Daily symptom monitoring is more sensitive and reliable than a questionnaire.

PubMed Disclaimer

Conflict of interest statement

Potential Competing Interests:

  1. Dr. Palsson is an author of the Rome III Diagnostic Questionnaire.

  2. Dr. Baggish was an employee of McNeil Consumer Health during the period this study was carried out.

  3. Ms. Turner has no competing interests.

  4. Dr. Whitehead is a member of the Board of the Rome Foundation and an author of the Rome III Diagnostic Questionnaire. He has received honoraria for participation on advisory boards for Takeda Pharmaceuticals and Ono Pharmaceuticals in the past 12 months.

Figures

Figure 1
Figure 1
Comparison of bowel symptoms of IBS patients on days with diarrhea, constipation or normal stool consistency. Means and standard errors are shown. All paired comparisons between Diarrhea Days, Normal Stool Days, and Constipation Days are significant at p<.05.
Figure 2
Figure 2
Symptom severity in different IBS subtypes on days with no bowel movements. Brackets show comparisons that are significant at p<.05.
See this image and copyright information in PMC

Comment in

References

    1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. In: Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, Whitehead WE, editors. Rome III: The Functional Gastrointestinal Disorders. Third. Vol. 2006. McLean, VA: Degnon Associates; pp. 487–555.
    1. Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29:329–341. - PubMed
    1. Johnston JM, Kurtz CB, MacDougall JE, Lavins BJ, Currie MG, Fitch DA, O'Dea C, Baird M, Lembo AJ. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterol. 2010;139:1877–1886. - PubMed
    1. Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, Ruegg P. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15:1655–1666. - PubMed
    1. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355:1035–1040. - PubMed

Publication types